KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on KVD900, KalVista’s lead drug program for oral on-demand treatment of hereditary angioedema (HAE) attacks, will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting 2022, taking place in Phoenix, AZ and virtually, from February 25-28, 2022. The presentations are:

• Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated With Early Symptom Relief in Patients With Hereditary Angioedema: Edward J. Duckworth, Senior Scientist Biochemistry, KalVista Pharmaceuticals, Inc. (Abstract/Poster #500). Results will be shared as a poster presentation on February 28, 2022 and online.

• Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary Angioedema: Paul Audhya MD, MBA, CMO KalVista Pharmaceuticals, Inc. (Abstract/Poster #509). Results will be shared as a poster presentation on February 28, 2022 and online.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.

Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 2 KOMPLETE clinical trial, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

KalVista Pharmaceuticals, Inc.
Ben Palleiko
CBO & CFO
857-999-0890
investors@kalvista.com